Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Avalo Therapeutics, Inc. NASDAQ:AVTX | $604.41M | $11.27 | Not rated | -3.6 | -60.39% |
Assembly Biosciences, Inc. NASDAQ:ASMB | $409.04M | $20.09 | Not rated | -64.4 | -37.31% |
Zura Bio Limited NASDAQ:ZURA | $371.82M | $3.88 | Not rated | -5.5 | -72.98% |
Enanta Pharmaceuticals, Inc. NASDAQ:ENTA | $323.29M | $11.10 | Not rated | -4.3 | -29.69% |
Nautilus Biotechnology, Inc. NASDAQ:NAUT | $262.15M | $2.06 | Not rated | -4.9 | +6.79% |
Eupraxia Pharmaceuticals Inc. NASDAQ:EPRX | $221.64M | $6.62 | Not rated | -8.5 | +3.92% |
Foghorn Therapeutics Inc. NASDAQ:FHTX | $109.86M | $1.85 | Not rated | -3.8 | -63.55% |
Pyxis Oncology, Inc. NASDAQ:PYXS | $106.44M | $1.68 | Not rated | -1.6 | -69.49% |
Tenaya Therapeutics, Inc. NASDAQ:TNYA | $85.36M | $0.38 | Not rated | -1.3 | -74.78% |
Caribou Biosciences, Inc. NASDAQ:CRBU | $50.38M | $0.47 | Not rated | -1.1 | -73.83% |
Continue the stock analysis
Jump to another research area for this company.